LIDDS: New Company Update and Market Valuation from Redeye

UPPSALA, SWEDEN – Lidds AB (publ)
Redeye has published a new LIDDS Company Update and Market Valuation, see below link:

https://liddspharma.com/news-and-media/#company-analysis

For additional information, please contact: 
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.

Attachment

• PR LIDDS 191209 Redeye Company Update